Levistilide a Induces Ferroptosis by Activating the Nrf2/HO-1 Signaling Pathway in Breast Cancer Cells

Shangwen Jing,Yantong Lu,Jing Zhang,Yan Ren,Yousheng Mo,Dongdong Liu,Lining Duan,Zhongyu Yuan,Changjun Wang,Qi Wang

DOI: https://doi.org/10.2147/DDDT.S374328

2022-09-08

Abstract:Shangwen Jing, 1, &ast Yantong Lu, 1, 2, &ast Jing Zhang, 1 Yan Ren, 1, 2 Yousheng Mo, 3 Dongdong Liu, 3 Lining Duan, 4 Zhongyu Yuan, 5 Changjun Wang, 2 Qi Wang 1 1 Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 2 Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Geriatric Institute, Guangzhou, People's Republic of China; 3 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 4 The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 5 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Changjun Wang; Qi Wang, Email ; Introduction: Breast cancer (BC) is the leading female malignancy, with one million new cases diagnosed worldwide per year. However, the current treatment options for BC patients have difficulty achieving satisfactory efficacy. Ferroptosis is a new mode of regulated cell death that plays a key role in the inhibition of tumorigenesis. Levistilide A (LA), as an active compound extracted from Chuanxiong Rhizoma, might prevent the development of tumors by regulating the critical cellular processes of ferroptosis. Methods: In this study, the underlying mechanisms of LA on ferroptosis in BC were explored in vitro. The effect of LA on the viability and mitochondrial function of BC cells was determined. Moreover, the effect of LA on the expression levels of key molecules involved in ferroptosis and the nuclear factor erythroid-2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) signaling pathway was evaluated. Results: LA significantly reduced cell viability and damaged the mitochondrial structure and function of BC cells in a dose-dependent manner. Furthermore, LA treatment markedly enhanced reactive oxygen species (ROS)-induced ferroptosis by activating the Nrf2/HO-1 signaling pathway. Conclusion: These findings suggest that LA may be a potential lead compound for breast cancer therapy by inducing ferroptosis in tumor cells. Keywords: breast cancer, levistilide A, ferroptosis, Nrf2/HO-1 signaling pathway Breast cancer (BC) is the leading female malignancy, with one million new cases diagnosed worldwide per year. 1 Although extensive progress has been made in the treatment of BC over the last few decades with surgery, targeted hormone therapy, chemotherapy and radiotherapy becoming the main treatment options for BC patients, the prognosis for BC patients remains poor because the efficacy of these interventions has been seriously compromised due to the emergence of multidrug resistance and obvious side effects. 2,3 Therefore, studies targeting effective treatment measures with minimal side effects are necessary to expand the existing therapeutic options for BC patients. Defects in the cell death executioner mechanism are the main reason for cancer treatment resistance. 4 Thus, the exploration of a new form of cell death is urgently needed in BC therapy. Ferroptosis is an entirely new mode of iron-dependent and reactive oxygen species (ROS)-dependent regulated cell death that was first identified in 2012. 5 Recent studies have pointed out that tumor cells have an increased demand for iron, which makes them more vulnerable to ferroptosis. 6 Furthermore, the higher growth rate and oxygen requirement induce tumor cells to experience more oxidative stress, which is a vital causative pathway to induce ferroptosis. 7 Importantly, increasing evidence has suggested that ferroptosis plays a key role in the inhibition of tumorigenesis by efficiently clearing damaged cells and maintaining microenvironment homeostasis. 8,9 The lethal depletion of glutathione (GSH) and glutathione peroxidase 4 (GPX4) arising from iron-dependent ROS accumulation contributes to the initiation of ferroptosis in cancer cells. 10 Recent studies revealed that erastin, a ferroptosis inducer, could remarkably increase the cytotoxic effects of cisplatin to effectively eliminate tumor cells. 11 Moreover, it was reported that GPX4-knockdown cells, which are sensitive to ferroptosis, had a higher survival rate than GPX4-positive cells in a diffuse large B-cell lymphoma in vitro model. 12 Additi -Abstract Truncated-